These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 29277815)

  • 1. The Outcome of Sorafenib Therapy on Unresectable Hepatocellular Carcinoma: Experience of Conversion and Salvage Hepatectomy.
    Yoshimoto T; Imura S; Morine Y; Ikemoto T; Arakawa Y; Iwahashi S; Saito YU; Takasu C; Ishikawa D; Teraoku H; Bando Y; Shimada M
    Anticancer Res; 2018 Jan; 38(1):501-507. PubMed ID: 29277815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete pathological response induced by sorafenib for advanced hepatocellular carcinoma with multiple lung metastases and venous tumor thrombosis allowing for curative resection.
    Kitajima T; Hatano E; Mitsunori Y; Taura K; Fujimoto Y; Mizumoto M; Okajima H; Kaido T; Minamiguchi S; Uemoto S
    Clin J Gastroenterol; 2015 Oct; 8(5):300-5. PubMed ID: 26249525
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
    Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
    World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recurrence-free survival of a hepatocellular carcinoma patient with tumor thrombosis of the inferior vena cava after treatment with sorafenib and hepatic resection.
    Nakamura K; Beppu T; Hayashi H; Okabe H; Imai K; Nitta H; Chikamoto A; Ishiko T; Sasaki M; Baba H
    Int Surg; 2015 May; 100(5):908-14. PubMed ID: 26011214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of long-term survivors following sorafenib treatment for advanced hepatocellular carcinoma: report of a workshop at the 50th Annual Meeting of the Liver Cancer Study Group of Japan.
    Tanaka K; Shimada M; Kudo M
    Oncology; 2014; 87 Suppl 1():104-9. PubMed ID: 25427741
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of hepatic arterial infusion chemotherapy versus sorafenib monotherapy in patients with advanced hepatocellular carcinoma.
    Kawaoka T; Aikata H; Hyogo H; Morio R; Morio K; Hatooka M; Fukuhara T; Kobayashi T; Naeshiro N; Miyaki D; Hiramatsu A; Imamura M; Kawakami Y; Takahashi S; Waki K; Tsuji K; Kohno H; Kohno H; Moriya T; Chayama K
    J Dig Dis; 2015 Sep; 16(9):505-12. PubMed ID: 26121102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
    Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
    Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of advanced hepatocellular carcinoma successfully treated by liver resection after complete response induced by sorafenib administration].
    Kim Y; Hosoda Y; Kakita N; Yamada Y; Yamasaki M; Nishino M; Okano M; Nagai K; Yasui M; Tsujinaka T
    Gan To Kagaku Ryoho; 2014 Nov; 41(12):2124-6. PubMed ID: 25731444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of surgical treatment after sorafenib therapy for advanced hepatocellular carcinoma.
    Takeyama H; Beppu T; Higashi T; Kaida T; Arima K; Taki K; Imai K; Nitta H; Hayashi H; Nakagawa S; Okabe H; Hashimoto D; Chikamoto A; Ishiko T; Tanaka M; Sasaki Y; Baba H
    Surg Today; 2018 Apr; 48(4):431-438. PubMed ID: 29110089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.
    Arao T; Ueshima K; Matsumoto K; Nagai T; Kimura H; Hagiwara S; Sakurai T; Haji S; Kanazawa A; Hidaka H; Iso Y; Kubota K; Shimada M; Utsunomiya T; Hirooka M; Hiasa Y; Toyoki Y; Hakamada K; Yasui K; Kumada T; Toyoda H; Sato S; Hisai H; Kuzuya T; Tsuchiya K; Izumi N; Arii S; Nishio K; Kudo M
    Hepatology; 2013 Apr; 57(4):1407-15. PubMed ID: 22890726
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sorafenib as an adjuvant therapy for resectable hepatocellular carcinoma: A single center experience.
    Antoniou EA; Margonis GA; Amini N; Anastasiou M; Angelou A; Kim Y; Kouraklis G
    J BUON; 2016; 21(5):1189-1194. PubMed ID: 27837622
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy of Sorafenib for Extrahepatic Recurrence of Hepatocellular Carcinoma after Liver Resection].
    Yokoo H; Kamiyama T; Kakisaka T; Orimo T; Wakayama K; Shimada S; Tsuruga Y; Kamachi H; Taketomi A
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):1497-9. PubMed ID: 26805075
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
    Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
    Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of patients with advanced hepatocellular carcinoma who achieved complete remission after sorafenib therapy.
    Park JG
    Clin Mol Hepatol; 2015 Sep; 21(3):287-94. PubMed ID: 26527250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete response to sorafenib in a patient with recurrent hepatocellular carcinoma.
    Huan HB; Lau WY; Xia F; Ma KS; Bie P
    World J Gastroenterol; 2014 Oct; 20(39):14505-9. PubMed ID: 25339839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hepatocellular carcinoma cases with high levels of c-Raf-1 expression may benefit from postoperative adjuvant sorafenib after hepatic resection even with high risk of recurrence.
    Lei J; Zhong J; Hao J; Liu Z; Zhang P; Wu L; Yan L; Zhu J; Zeng Y; Li B; Wen T; Wang W
    Oncotarget; 2016 Jul; 7(27):42598-42607. PubMed ID: 26981887
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Survival outcomes of hepatic resection compared with transarterial chemoembolization or sorafenib for hepatocellular carcinoma with portal vein tumor thrombosis.
    Lee JM; Jang BK; Lee YJ; Choi WY; Choi SM; Chung WJ; Hwang JS; Kang KJ; Kim YH; Chauhan AK; Park SY; Tak WY; Kweon YO; Kim BS; Lee CH
    Clin Mol Hepatol; 2016 Mar; 22(1):160-7. PubMed ID: 27044767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
    Liu D; Liu A; Peng J; Hu Y; Feng X
    Eur J Med Res; 2015 Feb; 20(1):12. PubMed ID: 25649133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
    Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
    BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Higher serum interleukin-17A levels as a potential biomarker for predicting early disease progression in patients with hepatitis B virus-associated advanced hepatocellular carcinoma treated with sorafenib.
    Cho HJ; Kim SS; Nam JS; Oh MJ; Kang DR; Kim JK; Lee JH; Kim B; Yang MJ; Hwang JC; Lim SG; Shin SJ; Lee KM; Yoo BM; Lee KJ; Cho SW; Cheong JY
    Cytokine; 2017 Jul; 95():118-125. PubMed ID: 28260649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.